CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
BIOLOGICAL

Nivolumab, Surgery, Radiotherapy

A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy

BIOLOGICAL

Nivolumab, Surgery, Chemoradiotherapy

A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy

Trial Locations (1)

CH634JY

Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Liverpool

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Clatterbridge Cancer Centre NHS Foundation Trust

OTHER

NCT03721757 - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer | Biotech Hunter | Biotech Hunter